期刊文献+

替格瑞洛用于氯吡格雷抵抗的经皮冠状动脉介入患者40例 预览 被引量:7

Percutaneous Coronary New Platelet Inhibitors Clopidogrel Resistance Ticagrelor for Patients Involved in 40 Cases
在线阅读 下载PDF
收藏 分享 导出
摘要 目的观察氯吡格雷抵抗的经皮冠状动脉介入(PCI)治疗患者采用替格瑞洛治疗的临床效果及安全性。方法选取医院收治的PCI患者80例,均经血栓弹力图(TEG)检查证实为氯吡格雷抵抗,随机分成试验组和对照组,各40例。对照组继续口服硫酸氢氯吡格雷片(75 mg,每日1次),试验组改用口服替格瑞洛片(90 mg,每日2次),同时服用阿司匹林肠溶片(100 mg,每日1次)。两组均连续用药3个月,随访3个月。结果治疗3个月后,对照组血小板计数为(198.21±86.62)×109/L,血小板聚集率为(44.51±8.65)%,二磷酸腺苷最大聚集时间为(63.21±56.21)s,二磷酸腺苷最大聚集率为(35.61±6.95)%,与试验组的(188.54±83.62)×109/L、(36.32±5.63)%、(178.51±89.65)s、(65.12±8.21)%相比,差异均有统计学意义(P〈0.05);随访3个月,试验组心血管事件发生率为5.00%,显著低于对照组的22.50%(P〈0.05);试验组出血发生率为2.50%,低于对照组的10.00%(P〉0.05)。结论替格瑞洛治疗氯吡格雷抵抗的PCI患者,疗效满意,安全性高,值得临床应用。 Objective To evaluate the ticagrelor treatment of percutaneous coronary intervention in patients with the clinical effects of clopidogrel resistance. Methods In our hospital percutaneous coronary intervention in patients with 80 cases, patients were selected by the TEG (thrombelastograph) were confirmed as clopidogrel resistance. By randomly selected cases will be divided into experimental and control groups with 40 patients in the control group continued clopidogrel therapy(75 mg / d, for 7 d), the experimental group received ticagrelor therapy (90 mg, 2 times / d, for 7 d), aspirin(100 mg, 1 times / d), for 3 weeks, follow - up 3 months. Results Platelet count was (198. 21 ± 86. 62) × 109 / L, platelet aggregation rate (44. 51 ± 8. 65)% , adenosine diphosphate maximum aggregate time (63. 21 ± 56. 21 ) s, the maximum aggregate rate of adenosine diphosphate It was (35. 61 ± 6. 95)% , and the control group (188. 54 ± 83. 62) × 109 / L, (36. 32 ± 5. 63)% , (178. 51 ± 89. 65) s, (65. 12 ± 8. 21)% , the difference was statistically significant( P〈 0. 05) . Experimental cardiovascular events was 5. 00% , significantly lower than the 22. 50% in the control group( P〈 0. 05); the experimental group, bleed-ing was 2. 50% , down from 10. 00% in the control group, but no significant difference between groups( P〉 0. 05) . Conclusion Tica-grelor therapy after percutaneous coronary intervention in patients with clopidogrel resistance results were satisfactory, safe, large hospitals at all levels learn applications.
作者 王星 浦奎 贾忠伟 Wang Xing, Pu Kui, Jia Zhongwei (254 Hospital of PLA, Tianfin, China 300000)
出处 《中国药业》 CAS 2015年第15期74-75,共2页 China Pharmaceuticals
关键词 替格瑞洛 氯吡格雷抵抗 冠状动脉介入 ticagrelor clopidogrel coronary intervention
  • 相关文献

参考文献10

二级参考文献266

  • 1刘文娴,吕树铮,陈立颖,卢燕玲.高龄急性冠脉综合征患者血运重建问题初探[J].中华急诊医学杂志,2004,13(8):545-547. 被引量:9
  • 2郭丽敏,崔炜.氯吡格雷抵抗的发生率及其影响因素[J].心血管病学进展,2005,26(2):120-123. 被引量:7
  • 3张言镇,赵丽梅,柳林,赵新祥,蔡跃红,吴玉萍.阿司匹林联合氯吡格雷治疗ST段抬高型急性心肌梗死的临床研究[J].潍坊医学院学报,2006,28(2):110-114. 被引量:15
  • 4蒋芳勇,孙立平.氯吡格雷在PCI中的应用[J].右江民族医学院学报,2006,28(5):858-859. 被引量:1
  • 5包承鑫.血小板的生物化学性能和分子生物学:血小板功能[M].//张之南,杨天楹,郝玉书.血液病学(下册).北京:人民卫生出版社,2003:1527-1534,1530-1532. 被引量:5
  • 6[4]SUKHOVA GK, SCHONBECK U, RABKIN E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheramatous plaques[J]. Circulation, 1999, 99(19):2503-2509. 被引量:1
  • 7[5]SHI GP, SUKHOVA GK, GRUBB A, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms[J]. J Clin Invest, 1999, 104(9):1191-1197. 被引量:1
  • 8[6]MACH F, SCHONBECK U, FABUNMI RP, et al. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation[J]. Am J Pathol, 1999, 154(1):229-238. 被引量:1
  • 9[7]De CATERINA R, LIBBY P, PENF HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines[J]. J Clin Invest, 1995, 96(1):60-68. 被引量:1
  • 10[8]BUSTOS C, HERNANDEZ-PRESA MA, ORTEGO M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis[J]. J Am Coll Cardiol, 1998, 32(7):2057-2064. 被引量:1

共引文献1431

同被引文献72

引证文献7

二级引证文献30

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈